German Ophthalmological Society (DOG) Honors Uta Gehlsen, PhD, with Prestigious Scientific Award for Her Research on the Use of Semifluorinated Alkanes in Dry Eye Treatment
The German Ophthalmological Society (DOG) presented Uta Gehlsen, PhD, Ocular Surface Group, Department of Ophthalmology, University of Cologne, with the “Dry Eye and Blepharitis/MGD” Award for her research related to the use of a semifluorinated alkane (SFA F4H5) as a novel carrier for cyclosporine A for the topical treatment of dry eye disease (DED).1
The DOG Awards recognize scientific and academic excellence, the advancement of young researchers, interdisciplinary and internationality in the field of ophthalmology. Sponsored by Optima Pharmazeutische GmbH, the award was presented on Saturday, September 30, 2017 during the 115th DOG Congress in Berlin.
Dr. Gehlsen’s research, which was published in Graefe’s Archive for Clinical and Experimental Ophthalmology in January 2017, found that a cyclosporine A formulation using F4H5 as its vehicle (CyclASol®, Novaliq) was equally effective but had a significantly faster therapeutic response in reducing the signs of DED compared to a commercially available treatment in an experimental mouse model.
Topical cyclosporine is a well-established medication used to treat signs of DED. It has anti-inflammatory effects and prevents T-cell activation. Clinical studies have shown that it is effective in reducing corneal staining and/or increasing tear production. Cyclosporine is also a highly lipophilic substance typically formulated as an emulsion which often causes adverse side effects with burning and stinging sensations due to the involved surfactants. The premise of the study was to learn whether a new SFA drug delivery system may improve efficacy or tolerability of cyclosporine.
“It is an honor to have been recognized by the DOG for our work in the area of SFA drug delivery technology and dry eye disease,” said Dr. Gehlsen. “Using the desiccating-stress dry-eye mouse model enables us to perform highly standardized pre-clinical in-vivo testing of topical therapies for inflammatory dry eye disease. Our experimental studies with several cyclosporine formulations hereby demonstrated a significantly faster and equally effective topical treatment effect for CyclASol® compared to other commercially available products. I am very pleased that our experimental results for CyclASol® have now been confirmed in the CYS-002 multicenter US clinical trial and hopefully will be soon available to treat patients suffering from dry eye disease.”
In this pre-clinical study, 0.05% cyclosporine dissolved in the F4H5 (CyclASol®) was found to be highly effective in reducing corneal staining and increasing tear production. Compared to the commercially available therapy comparator group, CyclASol® demonstrated at least a comparable therapeutic effect, but with a significantly faster response. Notably, early therapy with CyclASol® protected mice from developing dry eye, whereas all other study groups showed a significant increase of staining compared to baseline. CyclASol® also was the only studied treatment that demonstrated a prophylactic effect.
“On behalf of Novaliq, I congratulate Dr. Gehlsen for being presented with this award by the prestigious German Ophthalmological Society,” said Christian Roesky, PhD, managing director and CEO, Novaliq GmbH. “Through their research, we are better able to understand the many benefits of the SFA vehicle when added to traditionally insoluble or unstable drugs such as cyclosporine. Equipped with this knowledge, Novaliq has developed a very exciting and robust dry eye pipeline that has the potential to address significant unmet medical needs.”
About CyclASol ® – CyclASol® is a clear, preservative-free ophthalmic solution of cyclosporine A formulated using Novaliq’s proprietary EyeSol® drug delivery technology.
About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol ® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. Novaliq’s most advanced product is NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe. CyclASol ® a second-generation prescription drug is currently in preparation for a pivotal trial. More on www.novaliq.com.
About German Ophthalmological Society (DOG)—The DOG is the medical scientific association of ophthalmology in Germany and besides the oldest ophthalmological association in the world. It unites more than 7,000 ophthalmologists in hospitals, medical and research units. One of its main scopes is to advance scientific progress in ophthalmology and to transfer acknowledged findings into the daily routine in clinics and physicians’ practices.
1. Gehlsen U, Braun T, Notara M, Krösser S, Steven P; A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye; Graefes Arch Clin Exp Ophthalmol 2017; 255(4): 767-775
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Rockwell Automation Opens Registration for 2018 Automation Fair18.9.2018 14:54 | Pressemelding
Registration is now open for the 2018 Automation Fair, hosted by Rockwell Automation and members of its global PartnerNetwork program. The 27th annual Automation Fair will be held Nov. 12-15 at the Pennsylvania Convention Center. The event brings together approximately 10,000 manufacturers and producers from across the globe to learn about the newest innovations in automation and take part in training, industry forums and networking events. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005725/en/ Automation Fair will feature more than 150 exhibits showcasing the latest product innovations for industrial manufacturing and production. Hosted by Rockwell Automation and members of its PartnerNetwork, the event offers more than 400 hours of educational opportunities through forums, hands-on labs and technical sessions. (Photo: Business Wire) “The next industrial transformation is here – and meeting its demands requires a m
Seoul Semiconductor Supplies Optimal LEDs ‘SunLike’ to Large Scale Applications of Lumitronix in Germany18.9.2018 13:33 | Pressemelding
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a market leader in LED (light emitting diode) design and manufacturing, supplied the innovative LEDs “SunLike” to Lumitronix, the LED specialist located in Baden-Württemberg, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005626/en/ The Modules with SunLike LEDs. (Photo: Business Wire) In cooperation with Seoul Semiconductor, Lumitronix has also developed three optimal SunLike modules to provide customers with a standardized solution and expand its adoption in the lighting market. Two of the LED modules comply with the standard of Zhaga, a global association of lighting companies, for Book 7 L56W2 and Book 7 L28W2 and enable easy replacement in various industrial applications. The modules named LinearZ are available in one feet and two feet length. The model LinearZ 280-26 measures 280 mm and is equipped with 26 SunLike LEDs and has a light output of up to 700 lm.
Andersen Global Continues South American Expansion With BKM Berkemeyer18.9.2018 13:30 | Pressemelding
Andersen Global announces further growth in South America with the signing of a Collaboration Agreement with BKM Berkemeyer, one of the oldest and largest law firms in Paraguay. With two locations in the capital city of Asunción, the firm has a headcount of nearly 150 professionals, including ten Partners and over 60 lawyers. Established in 1951, BKM Berkemeyer is led by Managing Partner Hugo Berkemeyer and provides legal solutions to both domestic and international clients. The firm delivers advice in all areas of law, including business and corporate, taxation, litigation, environment, employment and intellectual property, with a notable expertise in international transactions and business matters. BKM Berkemeyer also specializes in M&A’s, joint ventures, foreign investment, infrastructure, project finance and financial transactions, advising also on issues regarding telecommunications, water and energy projects. Hugo commented, “Our focus at BKM Berkemeyer has been to provide flexib
175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis18.9.2018 13:05 | Pressemelding
Roughly 175 million Europeans have obstructive sleep apnoea, according to a late-breaking abstract presented by ResMed today at the European Respiratory Society’s annual ERS Congress in Paris. Leading researchers estimate 90 million Europeans have moderate to severe sleep apnoea, meaning they experience at least 15 breathing events an hour during sleep. These statistics are based on the latest scoring rules for determining one’s apnoea–hypopnoea index (AASM 2012) and are connected with a 16-country study announced in May 2018 that revealed an estimated 936 million people worldwide have sleep apnoea, a chronic sleep-disordered breathing condition associated with increased risk of mortality and reduced quality of life. The new global prevalence is nearly tenfold higher than the previous one – 100 million – estimated by the World Health Organization in 2007. European countries with the highest prevalence are: Russia, 40 million Germany, 26 million France, 24 million Ukraine, 13 million Sp
Loomis Sayles Announces Senior Loan Portfolio Manager Retirement18.9.2018 13:00 | Pressemelding
Loomis, Sayles & Company, an affiliate of Natixis Investment Managers, announced today that Kevin Perry, portfolio manager on the senior loan team, will retire in March 2019 after 17 years with the company and 37 years in the industry. All senior loan portfolios will continue to be co-managed by portfolio managers John Bell and Michael Klawitter, who have been members of the team for 17 and 16 years, respectively. The team oversees approximately $10.7 billion1 in institutional and retail assets for global clients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005187/en/ “Kevin has embodied Loomis Sayles’ values of collaboration, humility and prudent risk-taking every day since he and John joined us in 2001,” said Kevin Charleston, chief executive officer. “Kevin and John are considered pioneers in the bank loan market and their efforts have led to clients entrusting us with the management of more than $10 billion in b
SIA Has Provided the New Real-Time Gross Settlement System in Denmark18.9.2018 13:00 | Pressemelding
SIA, European hi-tech company, leader in payment infrastructures and services, has further strengthened its positioning in the Nordic countries, by providing Danmarks Nationalbank with the new real-time gross settlement system (RTGS) that connects banks, mortgage banks and settlement systems. This RTGS platform is already in operation by the central banks of Norway and Sweden and it will soon go live in Iceland too. The up-to-date technology infrastructure developed by SIA has replaced the previous in-house system that has been in use by the Central Bank of Denmark since 2001. The new RTGS system, that secures safe and real-time transfer of Danish kroner, ensures continued efficiency, operational reliability, functional sophistication and simpler maintenance of the system. In this initiative, SIA has used its wholly-owned subsidiary Perago, based in Pretoria (South Africa) and specialized in central bank solutions. Later this year, Denmark will be the first non-euro country to particip